1. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
- Author
-
Nguyen, Huyen, Kohl, Emily, Bade, Jessica, Eng, Stefan, Tosevska, Anela, Al Shihabi, Ahmad, Tebon, Peyton, Hong, Jenny, Dry, Sarah, Boutros, Paul, Panossian, Andre, Gosline, Sara, and Soragni, Alice
- Subjects
CP: Cancer biology ,CP: Stem cell ,HTS screening ,benign tumor ,cNF tumor organoids ,cutaneous neurofibroma ,neurofibroma ,neurofibromatosis type 1 ,organoids ,Humans ,Organoids ,Skin Neoplasms ,Neurofibroma ,Neurofibromatosis 1 - Abstract
Localized cutaneous neurofibromas (cNFs) are benign tumors that arise in the dermis of patients affected by neurofibromatosis type 1 syndrome. cNFs are benign lesions: they do not undergo malignant transformation or metastasize. Nevertheless, they can cover a significant proportion of the body, with some individuals developing hundreds to thousands of lesions. cNFs can cause pain, itching, and disfigurement resulting in substantial socio-emotional repercussions. Currently, surgery and laser desiccation are the sole treatment options but may result in scarring and potential regrowth from incomplete removal. To identify effective systemic therapies, we introduce an approach to establish and screen cNF organoids. We optimized conditions to support the ex vivo growth of genomically diverse cNFs. Patient-derived cNF organoids closely recapitulate cellular and molecular features of parental tumors as measured by immunohistopathology, methylation, RNA sequencing, and flow cytometry. Our cNF organoid platform enables rapid screening of hundreds of compounds in a patient- and tumor-specific manner.
- Published
- 2024